Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Dr. Mates said: "Medincell is entering a new era and I’m excited to help shape its future. Its vision and achievements closely align with my passion for advancing medical innova ...

Explore why TLX's strong sales, diverse pipeline, & theranostics promise support a 'Buy' rating, despite SEC concerns.

Organizations that neglect kindness face significant consequences, including employee turnover, absenteeism, eroded trust, ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

The European pharmaceutical industry said Tuesday that it remained concerned a EU-US trade deal reached at the weekend does ...

Sensodyne, the toothpaste first marketed in 1961 to reduce the pain of sensitive teeth, is among premium brands on sale in pharmacies and drug stores around the world. But if you live in an Indian ...

He joins a slew of Indians at the head of global firms both in the consumer space and in the tech world: Reports ...